Dr. Daniel Morgensztern, MD

Medicare patients and services

Medicare patients, 2024

332

Services billed

46,666

Patients’ average age

71

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 13 payments worth $18,882 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Missouri →

Industry-funded research

Named as a principal investigator on 13 industry-funded studies in 2025, from 10 companies. The companies reported $2,635,204 in research payments for these studies, mostly to the institutions running them.

• A First in Human Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 764532 administered by parenteral route in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expr…
  Boehringer Ingelheim Pharmaceuticals, Inc.
• A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
  Astellas Pharma Inc
• An Open-label, Phase I, Dose Escalation, Expansion Study of MGY825 in Adult Patients With Advanced Non-small Cell Lung Cancer
  Novartis Pharmaceuticals Corporation
• Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
  AbbVie Inc. · Active, not recruiting · NCT05599984
• SRF388-101
  Coherus Oncology, Inc.
• A phase 2 openlabel study of encorafenib binimetinib in patients with BRAFV600MUTANT nonsmall cell lung cancer
  Pfizer Inc.
• A phase 2 openlabel study of encorafenib binimetinib in patients with BRAFV600MUTANT nonsmall cell lung cancer
  Array Biopharma Inc
• Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult…
  AbbVie Inc.
• Encorafenibbinimetinib master protocol an openlabel continuation study for participants continuing from encorafenibbinimetinib clinical studies
  Pfizer Inc.
• A First in Human Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 764532 administered by parenteral route in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expr…
  Boehringer Ingelheim Pharma GmbH & Co.kg

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Saint Louis

• Camille N. Abboud, MD
• Ramzi Abboud, MD
• Foluso O. Ademuyiwa, MD
• Douglas R. Adkins, MD
• Stephen P. Allen, M.D.
• Nikolaos Andreatos, MD
• George Ansstas, MD
• Olivia Aranha, MD